GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Shiller PE Ratio

SLXN (Silexion Therapeutics) Shiller PE Ratio : (As of Mar. 31, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics Shiller PE Ratio?

Silexion Therapeutics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Silexion Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Silexion Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics Shiller PE Ratio Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Shiller PE Ratio
- - -

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Silexion Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Silexion Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silexion Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Silexion Therapeutics's Shiller PE Ratio falls into.


;
;

Silexion Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Silexion Therapeutics does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


Silexion Therapeutics  (NAS:SLXN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Silexion Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Silexion Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

Silexion Therapeutics Headlines

From GuruFocus